A version of this article was originally published by CancerNetwork®. This version has been lightly edited. The use of neoadjuvant chemotherapy (NACT) for less common epithelial ovarian cancers ...

The findings come amidst growing use of the treatment approach. Neoadjuvant chemotherapy (NACT) may be associated with poorer survival outcomes for certain patients with more uncommon types of ...

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Survival outcomes for patients with high-grade serous ovarian carcinoma may be ...

Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer A multi-institutional ...

Neoadjuvant chemotherapy (NACT) is a treatment for advanced ovarian cancer – cancer at stage III or IV. It uses chemo drugs to shrink tumors before any surgery is done to remove them. NACT uses a ...

—There has been a shift toward greater use of neoadjuvant chemotherapy in patients with advanced ovarian cancer. Is it the right choice? Reviewed by Vrunda Bhavsar Desai, MD, FACOG, Adjunct Assistant ...

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with HER2pos operable breast cancer treated with neo-adjuvant trastuzumab-containing chemotherapy.

Interval debulking surgery, or IDS, is a way to treat advanced – meaning stage III or IV – ovarian cancer when primary surgery isn’t possible. IDS also can be performed as a secondary surgery when ...

Giannopoulos et al. compared the parameters of surgical invasiveness between PDS-CT (n = 29) and NACT (n = 35) in the treatment of stage IIIC/IV ovarian cancer. [21] Patients treated with NACT were ...